SecProbe.io

CORRESP
 1
 filename1.htm

 GLOBAL INNOVATIVE PLATFORMS INC.

 149 James Place

 Orlando, Florida 32751

 (321) 230-3739

 May 13, 2025

 VIA EDGAR

 U.S. Securities and Exchange Commission

 Division of Corporation Finance

 100 F Street, N.E.

 Washington, D.C. 20549

 Re: 	Global Innovative Platforms Inc.

 Form 1-A Offering Statement File No. 024-12570

 Request for Acceleration of Qualification

 Ladies and Gentlemen:

 Pursuant to Rule 252(g) of Regulation A under the Securities
Act of 1933, as amended, Global Innovative Platforms Inc. (the "Company") hereby respectfully requests that the Securities
and Exchange Commission (the "Commission") accelerate the qualification of the Company's Offering Statement on Form
1-A (File No. 024-12570), including all amendments and exhibits thereto (the "Offering Statement"), to be effective as of
May 14, 2025, at 2:00 p.m. Eastern Time, or as soon thereafter as practicable.

 The Company acknowledges that:

 ● Should the Commission or the staff, acting pursuant to delegated authority,
declare the Offering Statement qualified, it does not foreclose the Commission from taking any action with respect to the Offering Statement;

 ● The action of the Commission or the staff, acting pursuant to delegated authority,
in declaring the Offering Statement qualified does not relieve the Company from its full responsibility for the adequacy and accuracy
of the disclosure in the Offering Statement; and

 ● The Company may not assert staff comments or the declaration of qualification
as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 Thank you for your attention to this matter.

 Sincerely,

 Global Innovative Platforms Inc.

 /s/Andrew Brown

 Andrew Brown, CEO

CORRESP
 1
 filename1.htm

 GLOBAL INNOVATIVE PLATFORMS INC.

 149 James Place

 Maitland, Florida 32751

 321-230-3739

 May 12, 2025

 Via Edgar

 Mr. Robert Augustin

 United State Securities and Exchange Commission

 Washington, D.C. 20549

 Re:

 Global Innovative Platforms Inc.

 Amendment No. 3 to Offering Circular on Form 1-A

 Filed April 30, 2025

 File No. 024- 12570

 Dear Mr. Augustin:

 The
following responses address the comments of the staff (the "Staff")
of the Securities and Exchange Commission as set forth in its letter dated May 8, 2025 (the "Comment Letter") relating to
the Amendment No. 2 to the Offering Circular on Form 1-A filed April 30, 2025 (the "Offering Circular") of Global Innovate
Platforms Inc. (the "Company").

 For
the Staff's convenience, the Staff's comments have been stated
below in their entirety followed by the corresponding responses from the Company.

 Amendment No. 2 to Offering Circular on Form 1-A

 Intellectual Property, page 37

 1. We note your disclosure on page 37 that "[a]ll patents are 20-year utility
patents that were awarded in the year indicated..." We also note your disclosure that various patents were issued during the years
1999 through 2004, thus having expired. Please revise to clarify which patents have expired in your table on page 37 or remove them from
the table. If material, please revise to disclose what effect you expect the expiration of these patents to have on your patent portfolio
and your business and if you intend to take any action to mitigate such effect, or advise. Additionally, to the extent your disclosure
regarding your proprietary technologies was based on these expired patents please revise such disclosure. Finally, please add risk factor
disclosure concerning your reliance on the Defiant Technologies Inc. License Agreement and May 8, 2025 Page 2 any risks associated with
your patent portfolio and any technology that is not patented.

 Response

 In
 response to the Staff's
comment, we have revised the Offering Circular to indicate which patents are expired. Please note that there is no material impact due
to the content underlying those patents having become obsolete. Regardless, we have also revised to include revised risk factors
 concerning our reliance on the Defiant Technologies Inc. License Agreement and any risks associated with your patent portfolio
and any technology that is not patented. Defiant Technologies (the licensor)
decided not to apply for new patents because they preferred not to disclose the new technology that replaced the expired patents. The
revised disclosure can be found on pages 7 and 37 of the amended Offering Circular.

 **********************

 Please do not hesitate to contact company counsel, Stephen Fleming, at 516-902-6567
if you have any questions or comments. Thank you.

 Sincerely,

 /s/Andrew
 Brown

 Andrew
 Brown, CEO

 cc:
 Stephen M. Fleming, Esq.

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 8, 2025

Andrew Brown
Chief Executive Officer
Global Innovative Platforms Inc.
149 James Place
Orlando, FL 32751

 Re: Global Innovative Platforms Inc.
 Amendment No. 2 to Offering Circular on Form 1-A
 Filed April 30, 2025
 File No. 024-12570
Dear Andrew Brown:

 We have reviewed your amended offering statement and have the following
comment(s).

 Please respond to this letter by amending your offering statement and
providing the
requested information. If you do not believe a comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

 After reviewing any amendment to your offering statement and the
information you
provide in response to this letter, we may have additional comments. Unless we
note
otherwise, any references to prior comments are to comments in our April 18,
2025 letter.

Amendment No. 2 to Offering Circular on Form 1-A
Intellectual Property, page 37

1. We note your disclosure on page 37 that "[a]ll patents are 20-year
utility patents that
 were awarded in the year indicated..." We also note your disclosure that
various
 patents were issued during the years 1999 through 2004, thus having
expired. Please
 revise to clarify which patents have expired in your table on page 37 or
remove them
 from the table. If material, please revise to disclose what effect you
expect the
 expiration of these patents to have on your patent portfolio and your
business and if
 you intend to take any action to mitigate such effect, or advise.
Additionally, to the
 extent your disclosure regarding your proprietary technologies was based
on these
 expired patents please revise such disclosure. Finally, please add risk
factor disclosure
 concerning your reliance on the Defiant Technologies Inc. License
Agreement and
 May 8, 2025
Page 2

 any risks associated with your patent portfolio and any technology that
is not patented.
 Please contact Robert Augustin at 202-551-8483 or Margaret Sawicki at
202-551-
7153 with any other questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Industrial
Applications and
 Services
cc: Stephen M. Fleming
</TEXT>
</DOCUMENT>

CORRESP
 1
 filename1.htm

 GLOBAL INNOVATIVE PLATFORMS INC.

 149 James Place

 Maitland, Florida 32751

 321-230-3739

 April 29, 2025

 Via Edgar

 Mr. Robert Augustin

 United State Securities and Exchange Commission

 Washington, D.C. 20549

 Re:

 Global Innovative Platforms Inc.

 Amendment No. 1 to Offering Circular on Form 1-A

 Filed April 4, 2025

 File No. 024-12570

 Dear Mr. Augustin:

 The
following responses address the comments of the staff (the "Staff") of the Securities and Exchange Commission as set forth
in its letter dated April 18, 2025 (the "Comment Letter") relating to the Amendment No. 1 to the Offering Circular on Form
1-A filed April 4, 2025 (the "Offering Circular") of Global Innovate Platforms Inc. (the "Company").

 For
the Staff's convenience, the Staff's comments have been stated below in their entirety followed by the corresponding responses
from the Company.

 Amendment No. 1 to Offering Statement on Form 1-A

 Plan of Distribution, page 16

 1. We note your response to prior comment 6 and your disclosure that "[w]e expect the initial closing
to occur within 90 days from the qualification of this offering by the SEC, provided the minimum offering amount is achieved." Revise
to reconcile with your cover page disclosure that "[t]his offering is being conducted on a best-efforts basis, which means that
there is no minimum number of Offered Shares that must be sold by us for this offering to close . . . ." To the extent you continue
to expect the initial closing to take place up to 90 days after qualification, please revise to explain why you expect to need such time
period to complete an initial closing.

 Response

 In response to the Staff's comment,
we have revised the Offering Circular to remove the statement on page 17 that "[w]e expect the initial closing to occur within 90
days from the qualification of this offering by the SEC, provided the minimum offering amount is achieved." This change ensures
consistency across the document and eliminate any implication of a minimum offering amount or a specific closing timeline. The revised
disclosure can be found on page 17 of the amended Offering Circular.

 Overview, page 25

 2. We note the graphic added to page 28. Please revise to describe what this graphic depicts, whether it
relates to your proof-of-concept study or the study conducted in October of 2024, and whether these are different studies. To the extent
they are different studies, please also revise to provide more detail concerning your proof-of concept study.

 Response

 We have revised the disclosure to describe
what the graphic depicts and that it was from the Development Study in October of 2024. We have clarified the names of our studies throughout
and labeled them appropriately.

 Business

 Heartworm Breath Test, page 30

 3. We note your response to prior comment 12 and your disclosure on page 31: "The Breath Capture Device
has been proven to adequately provide the appropriate amount of breath for a sample to be appropriately analyzed by the VOCAM Plus and
the FROG." Please revise to provide support for your statement that the Breath Capture Device is "proven." If the support
is your October 2024 study with eight samples then please revise to note the limited sample size.

 Response

 In response to the Staff's comment,
we have revised the disclosure on page 31 of the Offering Circular to remove the statement that the Breath Capture Device is "proven"
and instead clarify that the device has demonstrated functionality in preliminary testing. Specifically, we have noted that our Development
Study, conducted in October 2024 with a limited sample size of eight canine breath samples, showed that the Breath Capture Device can
collect sufficient breath for analysis by the VOCAM Plus and FROG systems. To provide additional context, we have included a reference
to the established use of Gas Chromatography-photoionization detectors in published studies of exhaled breath. We have also added a cautionary
statement acknowledging the preliminary nature of our study due to the small sample size and the need for further validation. These revisions
can be found in the "Business" section on page 31 of the amended Offering Circular.

 Business

 Our Competitive Strengths, page 32

 4. We note your revised disclosure that "[you] will be researching the ability to identify potentially
toxic environmental conditions for a multitude of animals." Please revise your disclosure to discuss the timeline to begin research
and the conditions and animals you plan to study, if known.

 Response

 We have revised the disclosure to indicate
that we do not have plans to pursue any other application than disease through breath at this time. We clarified the rights we have been
granted through our licensing agreement and what we have plans to actually pursue with pertinent time frames.

 Intellectual Property, page 37

 5. We note your revised disclosure in response to our prior comment 8 and reissue it in part. Please revise
your disclosure to provide the expiration dates and type of patent protection for each patent listed. We note certain patents include
method or process descriptions.

 Response

 In response to the Staff's comment, we have revised the
disclosure in the "Intellectual Property" section on page 37 of the Offering Circular to provide that the patents are twenty
year patents expiring twenty years after issuance. For clarity, we have also confirmed that all listed patents are utility patents under
U.S. patent law.

 * *********************

 Please do not hesitate to contact
company counsel, Stephen Fleming, at 516-902-6567 if you have any questions or comments. Thank you.

 Sincerely,

 /s/Andrew Brown

 Andrew Brown, CEO

 cc:
 Stephen M. Fleming, Esq.

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 18, 2025

Andrew Brown
Chief Executive Officer
Global Innovative Platforms Inc.
149 James Place
Orlando, FL 32751

 Re: Global Innovative Platforms Inc.
 Amendment No. 1 to Offering Circular on Form 1-A
 Filed April 4, 2025
 File No. 024-12570
Dear Andrew Brown:

 We have reviewed your amended offering statement and have the following
comment(s).

 Please respond to this letter by amending your offering statement and
providing the
requested information. If you do not believe a comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

 After reviewing any amendment to your offering statement and the
information you
provide in response to this letter, we may have additional comments. Unless we
note
otherwise, any references to prior comments are to comments in our March 10,
2025 letter.

Amendment No. 1 to Offering Statement on Form 1-A
Plan of Distribution, page 16

1. We note your response to prior comment 6 and your disclosure that "[w]e
expect the
 initial closing to occur within 90 days from the qualification of this
offering by the
 SEC, provided the minimum offering amount is achieved." Revise to
reconcile with
 your cover page disclosure that "[t]his offering is being conducted on a
best-efforts
 basis, which means that there is no minimum number of Offered Shares
that must be
 sold by us for this offering to close . . . ." To the extent you
continue to expect the
 initial closing to take place up to 90 days after qualification, please
revise to explain
 why you expect to need such time period to complete an initial closing.
 April 18, 2025
Page 2
Overview, page 25

2. We note the graphic added to page 28. Please revise to describe what
this graphic
 depicts, whether it relates to your proof-of-concept study or the study
conducted in
 October of 2024, and whether these are different studies. To the extent
they are
 different studies, please also revise to provide more detail concerning
your proof-of-
 concept study.
Business
Heartworm Breath Test, page 30

3. We note your response to prior comment 12 and your disclosure on page
31: "The
 Breath Capture Device has been proven to adequately provide the
appropriate amount
 of breath for a sample to be appropriately analyzed by the VOCAM Plus
and the
 FROG." Please revise to provide support for your statement that the
Breath Capture
 Device is "proven." If the support is your October 2024 study with eight
samples then
 please revise to note the limited sample size.
Business
Our Competitive Strengths, page 32

4. We note your revised disclosure that "[you] will be researching the
ability to identify
 potentially toxic environmental conditions for a multitude of animals."
Please revise
 your disclosure to discuss the timeline to begin research and the
conditions and
 animals you plan to study, if known.
Intellectual Property, page 37

5. We note your revised disclosure in response to our prior comment 8 and
reissue it in
 part. Please revise your disclosure to provide the expiration dates and
type of patent
 protection for each patent listed. We note certain patents include
method or process
 descriptions.

 Please contact Robert Augustin at 202-551-8483 or Margaret Sawicki at
202-551-
7153 with any other questions.

 Sincerely,

 Division of
Corporation Finance
 Office of
Industrial Applications and
 Services
cc: Stephen M. Fleming
</TEXT>
</DOCUMENT>

CORRESP
 1
 filename1.htm

 GLOBAL INNOVATIVE PLATFORMS INC.

 149 James Place

 Maitland, Florida 32751

 321-230-3739

 April 3, 2025

 Via Edgar

 Mr. Robert Augustin

 United State Securities and Exchange Commission

 Washington, D.C. 20549

 Re: Global Innovative Platforms Inc.
Offering Circular on Form 1-A
Filed February 12, 2025
File No. 024- 12570

 Dear Mr. Augustin:

 The
following responses address the comments of the staff (the "Staff") of the Securities and Exchange Commission as set forth
in its letter dated March 10, 2025 (the "Comment Letter") relating to the Offering Circular on Form 1-A filed February 12,
2025 (the "Offering Circular") of Global Innovate Platforms Inc. (the "Company").

 For
the Staff's convenience, the Staff's comments have been stated below in their entirety followed by the corresponding responses
from the Company.

 Form 1-A, filed February 12, 2025

 Cover Page

 1. We note that you plan to offer and sell shares of common stock "at
a fixed price of $0.50 per share (the price to be fixed by a post-qualification supplement)."
It is unclear to us how your proposed offering price will be set "at a fixed price" given the language that you will fix the
price by a post-qualification supplement. We also note your statement in Part I, where you selected the checkbox "yes" for
the question "[d]oes the issuer intend to price this offering after qualification pursuant to Rule 253(b)?" Please revise
your disclosure to clearly include either a fixed price or, pursuant to Rule 253(b)(2) of Regulation A, a bona fide price range within
which you presently plan to offer and sell securities.

 Response

 We have revised the Offering Circular to
indicate that the Company will be selling securities at a fixed price including removing the language stating that the price will be set
pursuant to a post-qualification supplement. Further, we have revised Part I to check the box "no" with respect to the above
referenced item.

 2. We note that your Selling Stockholders will offer their shares simultaneously
with the Company's offering. We also note that you "intend to sell the Company Offered Shares in this offering through the
efforts of [y]our Chief Executive Officer" who is also a Selling Stockholder. Please address the following:

 · explain how it will be determined whether the sale is for the benefit of the
 Company or for the account of the Selling Stockholders,

 · explain how investors will know if they are purchasing shares from you or the Selling Stockholders, and

 · revise the Use of Proceeds section and the Dilution section to show the effect of the primary and the
secondary offerings.

 Response

 Please note that we have removed the selling
stockholder component from the Offering Circular.

 3. We note that your offering statement contemplates 8,292,277 shares to be
offered by the Selling Stockholders and 1,400,000 shares to be offered by the Company. Please revise the resale portion to comply with
Rule 251(a)(3) of Regulation A, which restricts the selling securityholder component of a Company's initial offering and any subsequent
offering in the following 12 months to 30% of the aggregate offering price. We also note that your CEO is a Selling Stockholder yet in
Part I you selected the checkbox "no" for the question "[d]oes the proposed offering involve the resale of securities
by affiliates of the issuer?" Please revise or advise.

 Response

 Please note that we have removed
the selling stockholder component from the Offering Circular.

 Risk Factors, page 4

 4. We note your statement on page 4: "The business plan and operations
of the Company have been delayed over the course of the fiscal year ended September 30, 2024 and we expect further delays in implementing
our plan for when we will further our operations." Please revise to describe the cause for the delay in your business plan and operations
and the cause of the anticipated future delays.

 Response

 We have revised the disclosure to explain
that the delays were the result of the death of a critical consultant who was replaced. Further, we have revised to disclose that any
future delays could be caused by a number of factors, including, but not limited, to lake of access to capital.

 Plan of Distribution, page 16

 5. We note your statement on page 16: "Further, our Board of Directors
has determined that, in our company's sole discretion, we may issue Offered Shares in this offering for non-cash consideration,
including, without limitation, promissory notes, services and/or other consideration without notice to subscribers in this offering; provided,
however, that any Offered Shares issued in this manner shall be issued at the fixed price $0.50 per Offered Share." Please revise
to disclose all forms of non-cash consideration you intend to accept. Please also substantially revise your offering document, including
the Cover Page, Summary and Use of Proceeds sections, which all assume the offering will be made for cash only, to discuss the non-cash
consideration in more detail and to address how issuing some or all shares for non- cash consideration would impact your offering. Finally,
revise your risk factors to address the potential consequences to the Company if a substantial amount of shares is sold for non-cash consideration.
Please note that pursuant to Rule 253(b)(1) of Regulation A, if you include a price range instead of a fixed price, the securities must
be offered for cash.

 Response

 We have revised the Plan of Distribution
to remove the disclosure providing that the Company may take non-cash consideration.

 6. We note your disclosure regarding your Procedures for Subscribing and that
your subscription agreement gives the Company unlimited discretion to accept or reject subscriptions. Please provide expanded disclosure
regarding your subscription and closing process, including when the initial closing will occur, how you will inform investors of the closings,
and whether you may terminate the offering without ever having a closing. Please also provide disclosure regarding the details of your
process for accepting or rejecting subscriptions, including how soon after receipt of a subscription you will accept or reject such subscription,
what factors will go into deciding whether to accept or reject a subscription, and the process for returning proceeds to investors for
subscriptions that are rejected.

 Response

 We have revised the Plan of Distribution
to provide the requested expanded disclosure.

 Background, page 25

 7. Please also provide support for the following statement on page 25: "Our
team has proven credentials in the relevant spaces of commercializing animal healthcare, product development and operations from areas
ranging from genetic testing technologies, electronics, computer chip marketing, telecommunications and data, electronics equipment sales
and manufacturing, and food and beverage, among other skills. Several of the thirty plus product launches in our management's history
were highly novel, and 3 of those products became industry leaders."

 Response

 We have revised the Offering Circular to
discuss the credentials of management and the advisory board to support the above referenced statement.

 Business

 Overview of Business over the Last Five Years,
page 25

 8. We note your disclosure that on "[o]n August 18, 2023, the Company
entered into a Patent and Know-How License Agreement (the "License Agreement") with Defiant Technologies Inc." Please
expand your disclosure to discuss the material terms of such agreement, including without limitation, (i) each party's rights and
obligations, (ii) the aggregate amounts due under the agreement (we note that Defiant, at its discretion, may require a $225,000 lump
sum payment within 45 days of the effective date) (iii) the aggregate amounts paid to date (we note the initial payment of $50,000), (iv)
the term of the agreement, (v) the royalty term and royalty rate or range, (vi) the termination provisions and (vii) the aggregate future
potential milestone payments to be paid, as applicable. Please revise to file the agreement pursuant to Item 17(6) of Part III of Form
1-A. Additionally, we note your statement on page 39: "We do not have any intellectual property at this time." Please revise
to include a discussion of your licensed intellectual property, including from Defiant, which discussion should note, for each material
patent, (i) the specific products, product groups and technologies to which such patents relate, (ii) whether the patents are owned or
licensed, (iii) the type of patent protection, (iv) the patent expiration dates and (v) the jurisdiction.

 Response

 We have revised the disclosure on page 25
to provide a more exhaustive description of the License Agreement.

 We have added the License Agreement
as Exhibit 6.1 to the Offering Circular.

 We have revised the section titled "Business
Overview/Intellectual Property" to include a discussion of the licensed intellectual property with Defiant, noting each patent
and its involvement with each (i) the specific products, product groups and technologies to which such patents relate, (ii) whether the
patents are owned or licensed, (iii) the type of patent protection, (iv) the patent expiration dates and (v) the jurisdiction.

 Overview, page 27

 9. We note your statement that "[o]ver the next several months [you]
have verification and validation studies planned for the components and the Heartworm Breath Test." Please revise to describe your
plans and anticipated timeline for this and any other devices.

 Response

 We have revised th Overview section to further describe the testing
of the heartworm test including timeline.

 10. We note your disclosure on page 30 that "[you] were able to identify
with a small sample size to identify a breath print for the presence of heartworm in dogs without any false positives." Please revise
your disclosure to provide the material facts and findings of each trial you have conducted for any of your devices or their components.
For example, revise to clarify the scope, size and design of each trial (including who conducted and sponsored the trial), whether the
studies were powered to show statistical significance, the primary endpoints and whether any adverse events were observed in the studies,
as applicable, and discuss the findings and the significance of the results. Please also revise the graphics on page 30 so that they are
legible.

 Response

 We revised page 30 to include a
discussion of the small sample size.

 11. We note statements like the following on page 27: "Applications range
from disease and treatment effectiveness to potentially toxic environmental and food conditions" and "[w]e believe the technology
can also be used to identify toxic food conditions." Please revise to clarify, if true, that your future planned applications with
respect to food testing are limited to testing for mold on agriculture feed.

 Response

 We have revised throughout to provide that
we have no planned applications with respect to food testing presently.

 Heartworm Breath Test, page 32

 12. We note your statement on page 32: "Our Heartworm Breath Test, including
our Breath Collection Kit, is currently under development. The VOCAM Plus is already in production and has been tested successfully. The
A.I. software is complete and commercially available." Please revise to clarify what you mean by your statement that the VOCAM Plus
is "in production" when your test is not yet commercialized. Please also revise to clarify what you mean when you state that
 your A.I. software is "complete" and the meaning of "commercially available."
We note the device itself is not commercialized, and it appears the A.I. will process information from the device, which will only become
available once your device is in use. Please revise to describe whether this means customers can purchase your A.I. software separately
and the purpose of this software for their use.

 Response

 We have revised page 32 to further clarify
that each component that makes up our VOCAM Plus is functional.

 13. We note your statement on page 33, that you intend to allow your cloud-based
technology "to integrate with other popular platforms." You also state that "[t]he VOCAM Plus and FROG have the ability
to connect to a smart device." Please revise to further describe these platforms and how the VOCAM Plus and FROG connect to a smart
device.

 We have revised to provide that the technology
may be connected using Bluetooth or 5G technology.

 Compliance with Government Regulation, page 34

 14. We note your statement that you "are not aware of any pending or probable
regulations that would have an impact upon [y]our operations." We also note your statement on page 46: "We do not expect to
generate revenue from any product candidates that we develop until we obtain regulatory approval for one or more of such product candidates."
Please revise to include a description of existing governmental regulations applicable to your business, including the effects of the
Food and Drug Administration regulations on your business, such as any requirement for FDA approval of your products, including the Breath
Collection Device mentioned on page 32. We also note your statement on page 43 that you intend to seek and obtain approvals by trade associations.
Please describe these trade associations and their requirements.

 Response

 We have revised throughout to provide that
there are no FDA regulations that regulate the use of the product. We have also revised to more specifically discuss American Heartworm
Society and their potential for issuance of guidelines at their Triennial Symposium.

 Our Competitive Strengths, page 34

 15. We note that one of your competitive strengths is that you are more cost
effective than alternatives. Please revise to provide support for this statement or characterize it as management's belief.

 Response

 We have revised to provide an analysis of
our competitive strength and also characterized the statement as our belief.

 Exhibits

 16. Please revise the legal opinion filed as Exhibit 12.1 to cover the resale
 shares.

 Response

 As we have removed the selling stockholder
component from the Offering Circulate, there is no need to revise Exhibit 12.1.

 **********************

 Please do not hesitate to contact
company counsel, Stephen Fleming, at 516-902-6567 if you have any questions or comments. Thank you.

 Sincerely,

 /s/Andrew Brown

 Andrew
Brown, CEO

 cc:
 Stephen M. Fleming, Esq.

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 10, 2025

Andrew Brown
Chief Executive Officer
Global Innovative Platforms Inc.
149 James Place
Orlando, FL 32751

 Re: Global Innovative Platforms Inc.
 Offering Circular on Form 1-A
 Filed February 12, 2025
 File No. 024-12570
Dear Andrew Brown:

 We have reviewed your offering statement and have the following
comment(s).

 Please respond to this letter by amending your offering statement and
providing the
requested information. If you do not believe a comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response. After reviewing any amendment to your offering statement and the
information you
provide in response to this letter, we may have additional comments.

Form 1-A, filed February 12, 2025
Cover Page

1. We note that you plan to offer and sell shares of common stock "at a
fixed price of
 $0.50 per share (the price to be fixed by a post-qualification
supplement)." It is
 unclear to us how your proposed offering price will be set "at a fixed
price" given the
 language that you will fix the price by a post-qualification supplement.
We also note
 your statement in Part I, where you selected the checkbox "yes" for the
question
 "[d]oes the issuer intend to price this offering after qualification
pursuant to Rule
 253(b)?" Please revise your disclosure to clearly include either a fixed
price or,
 pursuant to Rule 253(b)(2) of Regulation A, a bona fide price range
within which you
 presently plan to offer and sell securities.
2. We note that your Selling Stockholders will offer their shares
simultaneously with the
 Company's offering. We also note that you "intend to sell the Company
Offered
 Shares in this offering through the efforts of [y]our Chief Executive
Officer" who is
 also a Selling Stockholder. Please address the following:
 explain how it will be determined whether the sale is for the
benefit of the
 March 10, 2025
Page 2

 Company or for the account of the Selling Stockholders,
 explain how investors will know if they are purchasing shares from
you or the
 Selling Stockholders, and
 revise the Use of Proceeds section and the Dilution section to
show the effect of
 the primary and the secondary offerings.
3. We note that your offering statement contemplates 8,292,277 shares to be
offered by
 the Selling Stockholders and 1,400,000 shares to be offered by the
Company. Please
 revise the resale portion to comply with Rule 251(a)(3) of Regulation A,
which
 restricts the selling securityholder component of a Company's initial
offering and any
 subsequent offering in the following 12 months to 30% of the aggregate
offering
 price. We also note that your CEO is a Selling Stockholder yet in Part I
you selected
 the checkbox "no" for the question "[d]oes the proposed offering involve
the resale of
 securities by affiliates of the issuer?" Please revise or advise.
Risk Factors, page 4

4. We note your statement on page 4: "The business plan and operations of
the Company
 have been delayed over the course of the fiscal year ended September 30,
2024 and
 we expect further delays in implementing our plan for when we will
further our
 operations." Please revise to describe the cause for the delay in your
business plan and
 operations and the cause of the anticipated future delays.
Plan of Distribution, page 16

5. We note your statement on page 16: "Further, our Board of Directors has
determined
 that, in our company s sole discretion, we may issue Offered Shares in
this offering
 for non-cash consideration, including, without limitation, promissory
notes, services
 and/or other consideration without notice to subscribers in this
offering; provided,
 however, that any Offered Shares issued in this manner shall be issued
at the fixed
 price $0.50 per Offered Share." Please revise to disclose all forms of
non-cash
 consideration you intend to accept. Please also substantially revise
your offering
 document, including the Cover Page, Summary and Use of Proceeds
sections, which
 all assume the offering will be made for cash only, to discuss the
non-cash
 consideration in more detail and to address how issuing some or all
shares for non-
 cash consideration would impact your offering. Finally, revise your risk
factors to
 address the potential consequences to the Company if a substantial
amount of shares
 is sold for non-cash consideration. Please note that pursuant to Rule
253(b)(1) of
 Regulation A, if you include a price range instead of a fixed price, the
securities must
 be offered for cash.
6. We note your disclosure regarding your Procedures for Subscribing and
that your
 subscription agreement gives the Company unlimited discretion to accept
or reject
 subscriptions. Please provide expanded disclosure regarding your
subscription and
 closing process, including when the initial closing will occur, how you
will inform
 investors of the closings, and whether you may terminate the offering
without ever
 having a closing. Please also provide disclosure regarding the details
of your process
 for accepting or rejecting subscriptions, including how soon after
receipt of a
 subscription you will accept or reject such subscription, what factors
will go into
 March 10, 2025
Page 3

 deciding whether to accept or reject a subscription, and the process for
returning
 proceeds to investors for subscriptions that are rejected.
Background, page 25

7. Please also provide support for the following statement on page 25: "Our
team has
 proven credentials in the relevant spaces of commercializing animal
healthcare,
 product development and operations from areas ranging from genetic
testing
 technologies, electronics, computer chip marketing, telecommunications
and data,
 electronics equipment sales and manufacturing, and food and beverage,
among other
 skills. Several of the thirty plus product launches in our management
s history were
 highly novel, and 3 of those products became industry leaders."
Business
Overview of Business over the Last Five Years, page 25

8. We note your disclosure that on "[o]n August 18, 2023, the Company
entered into a
 Patent and Know-How License Agreement (the "License Agreement") with
Defiant
 Technologies Inc." Please expand your disclosure to discuss the material
terms of
 such agreement, including without limitation, (i) each party's rights
and obligations,
 (ii) the aggregate amounts due under the agreement (we note that
Defiant, at its
 discretion, may require a $225,000 lump sum payment within 45 days of
the effective
 date) (iii) the aggregate amounts paid to date (we note the initial
payment of
 $50,000), (iv) the term of the agreement, (v) the royalty term and
royalty rate or
 range, (vi) the termination provisions and (vii) the aggregate future
potential
 milestone payments to be paid, as applicable. Please revise to file the
agreement
 pursuant to Item 17(6) of Part III of Form 1-A. Additionally, we note
your statement
 on page 39: "We do not have any intellectual property at this time."
Please revise to
 include a discussion of your licensed intellectual property, including
from Defiant,
 which discussion should note, for each material patent, (i) the specific
products,
 product groups and technologies to which such patents relate, (ii)
whether the patents
 are owned or licensed, (iii) the type of patent protection, (iv) the
patent expiration
 dates and (v) the jurisdiction.
Overview, page 27

9. We note your statement that "[o]ver the next several months [you] have
verification
 and validation studies planned for the components and the Heartworm
Breath Test."
 Please revise to describe your plans and anticipated timeline for this
and any other
 devices.
10. We note your disclosure on page 30 that "[you] were able to identify
with a small
 sample size to identify a breath print for the presence of heartworm in
dogs without
 any false positives." Please revise your disclosure to provide the
material facts and
 findings of each trial you have conducted for any of your devices or
their components.
 For example, revise to clarify the scope, size and design of each trial
(including who
 conducted and sponsored the trial), whether the studies were powered to
show
 statistical significance, the primary endpoints and whether any adverse
events were
 observed in the studies, as applicable, and discuss the findings and the
significance of
 the results. Please also revise the graphics on page 30 so that they are
legible.
 March 10, 2025
Page 4

11. We note statements like the following on page 27: "Applications range
from disease
 and treatment effectiveness to potentially toxic environmental and food
conditions"
 and "[w]e believe the technology can also be used to identify toxic food
conditions."
 Please revise to clarify, if true, that your future planned applications
with respect to
 food testing are limited to testing for mold on agriculture feed.
Heartworm Breath Test, page 32

12. We note your statement on page 32: "Our Heartworm Breath Test, including
our
 Breath Collection Kit, is currently under development. The VOCAM Plus is
already
 in production and has been tested successfully. The A.I. software is
complete and
 commercially available." Please revise to clarify what you mean by your
statement
 that the VOCAM Plus is "in production" when your test is not yet
 commercialized. Please also revise to clarify what you mean when you
state that your
 A.I. software is "complete" and the meaning of "commercially available."
We note the
 device itself is not commercialized, and it appears the A.I. will
process information
 from the device, which will only become available once your device is in
use. Please
 revise to describe whether this means customers can purchase your A.I.
software
 separately and the purpose of this software for their use.
13. We note your statement on page 33, that you intend to allow your
cloud-based
 technology "to integrate with other popular platforms." You also state
that "[t]he
 VOCAM Plus and FROG have the ability to connect to a smart device."
Please revise
 to further describe these platforms and how the VOCAM Plus and FROG
connect to a
 smart device.
Compliance with Government Regulation, page 34

14. We note your statement that you "are not aware of any pending or
probable
 regulations that would have an impact upon [y]our operations." We also
note your
 statement on page 46: "We do not expect to generate revenue from any
product
 candidates that we develop until we obtain regulatory approval for one
or more of
 such product candidates." Please revise to include a description of
existing
 governmental regulations applicable to your business, including the
effects of the
 Food and Drug Administration regulations on your business, such as
 any requirement for FDA approval of your products, including the Breath
Collection
 Device mentioned on page 32. We also note your statement on page 43 that
you
 intend to seek and obtain approvals by trade associations. Please
describe these trade
 associations and their requirements.
Our Competitive Strengths, page 34

15. We note that one of your competitive strengths is that you are more cost
effective than
 alternatives. Please revise to provide support for this statement or
characterize it as
 management's belief.
Exhibits

16. Please revise the legal opinion filed as Exhibit 12.1 to cover the
resale shares.
 March 10, 2025
Page 5

 We will consider qualifying your offering statement at your request. If
a participant in
your offering is required to clear its compensation arrangements with FINRA,
please have
FINRA advise us that it has no objections to the compensation arrangements
prior to
qualification.

 We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff. We also remind you that, following qualification of
your Form 1-A,
Rule 257 of Regulation A requires you to file periodic and current reports,
including a Form
1-K which will be due within 120 calendar days after the end of the fiscal year
covered by the
report.

 Please contact Robert Augustin at 202-551-8483 or Margaret Sawicki at
202-551-
7153 with any other questions.

 Sincerely,

 Division of
Corporation Finance
 Office of
Industrial Applications and
 Services
cc: Stephen M. Fleming
</TEXT>
</DOCUMENT>

United States securities and exchange commission logo
February 12, 2021
David Cutler
Chief Executive Officer
Canning Street Corp
PO Box 140271
Lakewood, Colorado, 80214
Re:Canning Street Corp
Form 10-12G/A filed January 28, 2021
File No. 000-56235
Dear Mr. Cutler :
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction

CORRESP
1
filename1.htm

Michael
A. Littman

Attorney
at Law

PO
Box 1839

Arvada,
CO 80001

(720)
530-6184

malattyco@aol.com

January 28, 2021

VIA EDGAR CORRESPONDENCE

Securities and Exchange Commission

Division of Corporation Finance

Office of Real Estate and Construction

Washington, D. C. 20549

Re:

Canning Street Corp.

Form 10-12G 	Filed December 29,
2020

File No. 000-56235

Dear Commission,

In response to the
Commission’s letter dated January 22, 2021 in the matter referenced above, an amended Form 10 has been filed on the EDGAR
system. Below please find the following answers addressed in the amendment:

Form 10-12G filed December 29, 2020

Report of Independent Registered
Public Accounting Firm, page F-31.

We note your disclosure
on page 30 that your independent auditor was appointed on December 30, 2020. However, we note that the audit report is signed by
your independent auditor on December 28, 2020. Please clarify and/or revise this apparent discrepancy.

ANSWER:

Please note that five
dates have been changed in the amendment. First, under Item 13, page 30, September 15, 2018 to September 15, 2020 (Inception),
secondly, under Item 14, page 30, December 30, 2020 to December 10, 2020 to address your comment above, thirdly, the Statement
of Cash Flow, page F-7, the date in the header of the table has been changed from September 30, 2020 (Inception) to September
15, 2020 (Inception), and lastly, under Note 7. Income Taxes, page F-13, both header dates in each of the tables.

We hope this amendment
meets with your satisfaction.

Sincerely,

/s/ Michael A. Littman

Michael A. Littman

Attorney at Law

United States securities and exchange commission logo
January 22, 2021
David Cutler
Chief Executive Officer
Canning Street Corp
PO Box 140271
Lakewood, Colorado, 80214
Re:Canning Street Corp
Form 10-12G filed December 29, 2020
File No. 000-56235
Dear Mr. Cutler :
            We have reviewed your filing and have the following comment.
            Please respond to our comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond.  If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
            After reviewing your response and any amendment you may file in response to our
comment, we may have additional comments.
Form 10-12G filed December 29, 2020
Report of Independent Registered Public Accounting Firm, page F-3
1.We note your disclosure on page 30 that your independent auditor was appointed on
December 30, 2020.  However, we note that the audit report is signed by your independent
auditor on December 28, 2020.  Please clarify and/or revise this apparent discrepancy.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

 FirstName LastNameDavid Cutler
 Comapany NameCanning Street Corp
 January 22, 2021 Page 2
 FirstName LastName
David Cutler
Canning Street Corp
January 22, 2021
Page 2
            You may contact Jeffrey Lewis at 202-551-6216 or Kristina Marrone at 202-551-3429 if
you have questions regarding comments on the financial statements and related matters.  Please
contact Todd Schiffman at 202-551-3491 or James Lopez at 202-551-3536 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction